Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,430 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Restless Legs Syndrome
Interventions: buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opiate Substitution Treatment, Opioid-Related Disorders
Interventions: Liraglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions: Ketamine; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 10 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Idiopathic Intracranial Hypertension
Interventions: Acetazolamide, Placebo, Formal weight loss counselling program; Drug · Behavioral
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more

Conditions: Healthy
Interventions: Buprenorphine HCl/Naloxone HCl; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain
Interventions: Not listed
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcohol Use Disorder, Severe
Interventions: Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage; Drug · Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Major Depressive Disorder, Depression
Interventions: Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.; Drug · Device
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Opioid Dependence
Interventions: buprenorphine/naloxone combination; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Drug Dependence
Interventions: Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil; Drug · Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Opioid Use, Sedative Use
Interventions: Opioid Agonist, Sedatives; Drug
Lead sponsor: Sharon Walsh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Total Knee Arthroplasty
Interventions: Oxycodone, Placebo Oral Tablet; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Smoking Cessation, Smoking, Cigarette, Nicotine Dependence
Interventions: AXS-05, Bupropion SR; Drug
Lead sponsor: James Davis; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Artery Disease
Interventions: Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine, Midazolam; Other · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Perioperative Optimization
Interventions: Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1; Drug
Lead sponsor: Jennifer Holder-Murray; Other
Eligibility: 18 Years and older
Enrollment: 3,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania, Manic State
Interventions: Pentazocine, Lorazepam; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 25 Years to 51 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Bladder Pain Syndrome, Interstitial Cystitis
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Heroin Dependence, Opioid-Related Disorders
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Opiate Addiction, Refractory Pain
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Malignant Glioma
Interventions: LDN, Placebo; Drug
Lead sponsor: Katy Peters; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Butrans for Treatment of Restless Legs Syndrome

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

Buprenorphine Detox With Two Types of Treatment. BBD I - 10

Idiopathic Intracranial Hypertension Treatment Trial

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

Brain Response to Pain Control in People With Chronic Pain

Inpatient Single Dose Interventions for Alcohol Use Disorder

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse

Drug Discrimination in Methadone-Maintained Humans Study 1

Prescription Medication Interactions

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

AXS-05 Phase II Trial on Smoking Behavior

The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

Buprenorphine Combination Tablet Feasibility - 1

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

Alternate Day Buprenorphine Administration, Phase XI - 16

Low-dose Naltrexone for Bladder Pain Syndrome

Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions

Effects of Environmental Factors on Opiate Drug Choice in Opioid Dependent Individuals.

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

Low Dose Naltrexone for Glioma Patients